CompletedEUCTR 2004-004461-15
SOLIAN solution in the acute setting
This historical record does not confirm current site availability.
Historical research recordBelgiumSchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 500
- Sponsor
- SANOFI-SYNTHELABO
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2004-004461-15
- Official title
Show the full official title
SOLIAN solution in the acute setting
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium
Registry details
Historical country statuses
- Belgium — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is SANOFI-SYNTHELABO.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication